Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is anticipated to announce its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $0.78 per share and revenue of $185.38 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Pacira BioSciences Trading Up 0.4 %

PCRX opened at $25.25 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The firm has a market capitalization of $1.17 billion, a PE ratio of -12.44 and a beta of 0.80. The company’s 50-day moving average is $22.60 and its 200 day moving average is $18.29.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Needham & Company LLC increased their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Barclays decreased their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright restated a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and raised their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and an average price target of $22.78.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.